Oncotelic Therapeutics
- Biotech or pharma, therapeutic R&D
Developer of TGFB2 ASO. In phase 3 against PDAC and GBM. Developer of deciparticles- sub 20 nm nanoparticles. Pipeline of six 505b2 candidates- INDs in 2025 with expected commercialization in 2027. We are looking to outlicense our technologies as well as in license additional technologies that complement ours.
Address
Agoura HillsCalifornia
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}